Mineralys Therapeutics ($MLYS) Posts Wider Q3 Loss Ahead of December FDA Decision Mineralys Therapeutics reported a third quarter 2026 net loss of $57.3 millio

Mineralys Therapeutics ($MLYS) Posts Wider Q3 Loss Ahead of December FDA Decision Mineralys Therapeutics reported a third quarter 2026 net loss of $57.3 million, widening from $36.9 million in the same period a year earlier. Net loss per share came in at $0.64, missing the consensus estimate of ro…